Join the Asia Pacific content team for a wide-ranging overview and analysis of recent developments across China, India, South Korea and Japan in the policy, regulatory, commercial and vaccines spaces over the past few months. 

Join the Asia Pacific content team for a wide-ranging overview and analysis of recent developments across China, India, South Korea and Japan in the policy, regulatory, commercial and vaccines spaces over the past few months. 

In this week's podcast edition of Five Must-Know Things: the prospects and plans for J&J’s pharma and oncology business; China looks more inward under new policies; an important US approval for Takeda; and Moderna’s co-founder shares tips on innovation.

Japanese firm and key discoverer of immuno-oncology protein reach settlement of patent-related dispute that includes formation of new academic research fund. 

Plus deals involving Zai Lab/Karuna, Zai Lab/Blueprint, Lotus/PharmaMar, Nippon Shinyaku/Dynacure, Alphamab/Ascletis, Aptose/Hanmi, Shanghai Pharmaceuticals/HUYABIO, KoBioLabs/SPH Sine, CURACLE/ Théa Open Innovation, Signet/XtalPi, Curi Bio/NEXEL, CANbridge/Scriptr and Ligand/CRDC.

In this week's podcast edition of Five Must-Know Things: Pfizer’s "game-changing" COVID-19 oral antiviral results; Novartis sells Roche stake; Novartis trumps productive pipeline; Bayer sees blockbuster status for hot flashes drug; and continued hesitance over Aduhelm in the US.